
Thyroid eye disease (TED) is an autoimmune orbital disorder primarily affecting Graves’ hyperthyroid patients. It presents with varying severity and involves inflammation, proptosis, and optic neuropathy. Teprotumumab, targeting IGF-1R, shows superior outcomes in moderate-to-severe TED but has notable limitations. Steroids remain the global standard, while tocilizumab offers an option for steroid-resistant cases. Multidisciplinary care and quality-of-life evaluations are essential for comprehensive TED management.
Like
Save
Share